GoodRx (NASDAQ:GDRX) Shares Gap Up - Still a Buy?

Key Points

• GoodRx shares saw a significant price increase, gapping up from a previous close of $3.73 to an opening price of $4.65, and last traded at $5.03 with substantial trading volume.
• Wall Street analysts have adjusted their price targets for GoodRx, with Goldman Sachs lowering theirs from $6.00 to $5.00, indicating a cautious outlook with a "neutral" rating.
• The company's latest earnings report revealed a miss in EPS expectations, posting $0.09 against the $0.10 consensus, and a slight 1.2% increase in quarterly revenue compared to the previous year.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $3.73, but opened at $4.65. GoodRx shares last traded at $5.03, with a volume of 10,672,040 shares.

Analyst Upgrades and Downgrades

GDRX has been the subject of several analyst reports. The Goldman Sachs Group cut their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Wells Fargo & Company cut their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial downgraded shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Finally, UBS Group lowered their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, GoodRx currently has an average rating of "Hold" and a consensus price target of $5.80.

GoodRx Stock Up 1.6%

The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. The firm has a market capitalization of $1.58 billion, a PE ratio of 45.60, a PEG ratio of 1.96 and a beta of 1.24. The company's 50 day simple moving average is $4.58 and its 200-day simple moving average is $4.50.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The business's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share. On average, analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.53% of the company's stock.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citizens Financial Group Inc. RI purchased a new stake in shares of GoodRx during the 1st quarter valued at $44,000. Jump Financial LLC purchased a new stake in shares of GoodRx during the 1st quarter valued at $49,000. Cetera Investment Advisers purchased a new stake in shares of GoodRx during the 2nd quarter valued at $50,000. Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of GoodRx during the 2nd quarter valued at $55,000. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of GoodRx during the 4th quarter valued at $56,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.